Anteris Q1 net loss $21.9M (up 36%); sales $0.6M (-27%); DurAVR IDE submitted

Anteris Technologies Global Corp.

2025-Q1 EPS reported -$0.61 revenue$556,000

Net loss $21.9M vs $16.2M a year ago; revenue $0.6M down 27% on lower tissue demand.
R&D spend $16.5M (+42%) driven by manufacturing scale-up ($3.5M) and PARADIGM trial prep ($1.5M).
Cash at March 31: $49.0M; IPO green-shoe raised $0.47M; included in Russell 2000.
DurAVR THV IDE for pivotal PARADIGM Trial submitted to FDA; 100+ patients treated; one-year data shows EOA 2.1 cm², MPG 8.6 mmHg, no valve mortality.
Manufacturing capacity scaled to 3x 2024 levels; ADAPT tissue sourced from US and Australia to mitigate supply risk.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.